<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886756</url>
  </required_header>
  <id_info>
    <org_study_id>D1960C00003</org_study_id>
    <secondary_id>2009-009940-22</secondary_id>
    <nct_id>NCT00886756</nct_id>
  </id_info>
  <brief_title>AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects</brief_title>
  <acronym>JSAD</acronym>
  <official_title>A Phase I, Single-Centre, Randomised, Double-Blind, Placebo Controlled Single-Ascending Dose, Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD8529 in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, double-blind, placebo-controlled, randomised within each dose group,
      single ascending dose study, with the objective to assess the safety, tolerability and
      pharmacokinetic profile of AZD8529 in healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To asses the safety:Adverse events, vital signs, physical examinations, telemetry, dECGs, clinical chemistry and haematology labs including testosterone, prolactin, LH, FSH and TSH, and urinalysis.</measure>
    <time_frame>From screening period to follow-up, 42 days (maiximum).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of AZD8529 in plasma and urine.</measure>
    <time_frame>Blood and urine sampling from pre-dose until 12 days post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To collect and store DNA for future exploratory research</measure>
    <time_frame>One blood sampling after randomisation.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8529</intervention_name>
    <description>Oral</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male Japanese subjects aged 20 to 45 years (inclusive)

          -  Have a body mass index (BMI) between 18 and 27 kg/m 2 (inclusive) and weigh at least
             50 kg.least 50 kg.

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study.

          -  Any clinically relevant abnormalities in physical examinations, vital signs, clinical
             chemistry, haematology or urinalysis as judged by the Investigator and/or Sponsor.

          -  Smoking in excess of 5 cigarettes per day or the equivalent within 28 days of Day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Lorch, MD MFPM FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>August 18, 2009</last_update_submitted>
  <last_update_submitted_qc>August 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>AstraZeneca, MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Japanese healthy volunteer</keyword>
  <keyword>AZD8529</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

